A new approach to the development of anti-ischemic drugs: protective drugs against cell injury induced by lysophosphatidylcholine.
Recent studies have revealed that lysophosphatidylcholine (LPC) produces mechanical and metabolic derangements in perfused working rat hearts and Ca2+-overload in isolated cardiac myocytes. Thus, LPC possesses an ischemia-like effect on the heart. Therefore, a drug that possesses an anti-LPC action would protect or improve ischemia/reperfusion damage. We examined the effects of various anti-ischemic drugs on the Ca2+ overload induced by LPC. Our data suggest that a drug with high lipophilicity possesses a protective effect on cell injury induced by LPC, probably because of preservation of membrane integrity.
Hashizume
H
H
Department of Pharmacology, Asahikawa Medical College, Japan.
Chen
M
M
Ma
H
H
Hara
A
A
Yazawa
K
K
Akahira
M
M
Xiao
C Y
CY
Abiko
Y
Y
D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000818:Animals; D002118:Calcium / Q000378:metabolism; D002121:Calcium Channel Blockers / Q000494:pharmacology; D006321:Heart / Q000187:drug effects; D008244:Lysophosphatidylcholines / Q000037:antagonists & inhibitors* / Q000633:toxicity; D017202:Myocardial Ischemia / Q000139:chemically induced / Q000188:drug therapy*; D009206:Myocardium / Q000378:metabolism; D051381:Rats
D000319:Adrenergic beta-Antagonists; D002121:Calcium Channel Blockers; D008244:Lysophosphatidylcholines; D002118:Calcium